Trial · NCT02760498
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 59 | |
| Overall Study | STARTED | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 78 | |
| Overall Study | STARTED | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 56 | |
| Overall Study | STARTED | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 63 | |
| Overall Study | STARTED | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | 9 | |
| Overall Study | STARTED | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W | 167 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 59 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 78 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 56 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 63 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | 9 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W | 165 | |
| Overall Study | Completed Treatment | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 24 | |
| Overall Study | Completed Treatment | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 20 | |
| Overall Study | Completed Treatment | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 22 | |
| Overall Study | Completed Treatment | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 27 | |
| Overall Study | Completed Treatment | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | 5 | |
| Overall Study | Completed Treatment | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W | 50 | |
| Overall Study | COMPLETED | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 19 | |
| Overall Study | COMPLETED | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 28 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02760498/flow